Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.23 USD
Change Today -0.026 / -1.15%
Volume 8.5K
GNVC On Other Exchanges
As of 10:47 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

genvec inc (GNVC) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/9/15 - $4.67
52 Week Low
10/15/14 - $1.61
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GENVEC INC (GNVC)

genvec inc (GNVC) Related Bloomberg News

View More Bloomberg News

genvec inc (GNVC) Related Businessweek News

No Related Businessweek News Found

genvec inc (GNVC) Details

GenVec, Inc., a clinical-stage biopharmaceutical company, focuses on using its adenovector gene delivery platform to develop a pipeline of therapeutics and vaccines in the United States. The company develops its product candidates through collaborations with various companies and organizations, including Novartis AG, Merial Limited, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of various human and animal health concerns. Its lead product candidate includes CGF166, which is in Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. The company also develops vaccines against infectious diseases, including respiratory syncytial virus, herpes simplex virus, Enterovirus D68, and malaria, as well as vaccines against foot-and-mouth disease in the area of animal health. It has a collaboration agreement with TheraBiologics to develop cancer therapeutics. The company was founded in 1992 and is based in Gaithersburg, Maryland.

11 Employees
Last Reported Date: 03/24/15
Founded in 1992

genvec inc (GNVC) Top Compensated Officers

Chief Executive Officer, President, Corporate...
Total Annual Compensation: $375.0K
Senior Vice President of Development
Total Annual Compensation: $278.1K
Chief Scientific Officer
Total Annual Compensation: $310.7K
Compensation as of Fiscal Year 2014.

genvec inc (GNVC) Key Developments

GenVec, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

GenVec, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the three months ended March 31, 2015, the company reported a net loss of $1.5 million, or $0.09 per share, on revenues of $0.4 million, compared with a net loss of $1.0 million, or $0.07 per share, on revenues of $2.1 million, for the same period in the prior year. The decrease in revenue for the three-month period ended March 31, 2015 is primarily a result of a decrease in revenue of $1.9 million associated with its hearing loss and balance disorders program with Novartis. This lower revenue resulted mainly from the achievement of a $2 million milestone in the collaboration during the first quarter of 2014, with no corresponding achievement in the first quarter of 2015. This decrease was partially offset by an increase in revenue of $0.2 million associated with its animal health program due to increased work scope. Operating loss was $1.536 million against $0.964 million a year ago.

GenVec, Inc. Appoints Michael Richman as Director

GenVec, Inc. announced that the Board of Directors of GenVec, Inc. appointed Michael Richman as a director of the company. Mr. Richman has served as the president and chief executive officer of Amplimmune, a member of the AstraZeneca group since 2013.  Prior to Amplimmune's acquisition by AstraZeneca, he was president and chief executive officer of the company when it was a privately held biologics company focused on cancer and autoimmune diseases.

GenVec, Inc. Announces Collaboration with Laboratory of Malaria Immunology & Vaccinology of the National Institute

GenVec, Inc. announced that it has signed a research collaboration agreement with the Laboratory of Malaria Immunology and Vaccinology of the National Institute (LMIV) of Allergy and Infectious Diseases, National Institutes of Health. The research collaboration will utilize GenVec's proprietary gorilla adenovirus vectors to deliver a number of novel antigens discovered at the LMIV in order to create and test a variety of malaria vaccine candidates.  GenVec will construct vaccine candidates at its laboratories and hand them off to LMIV's Vaccine Development Unit, which is headed by Patrick E. Duffy, M.D., for preclinical testing. The focus of this joint approach is to devise vaccines that block the transmission of the deadliest malaria-causing parasite, Plasmodium falciparum, by triggering the production of antibodies that are taken up by a mosquito when it bites a vaccinated individual. This differentiated approach launches an attack on the parasite while it is in its mosquito carrier and could potentially help stop the spread of the disease to subsequent bite victims.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNVC:US $2.23 USD -0.026

GNVC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $23.17 USD +0.189
Argos Therapeutics Inc $7.68 USD +0.05
Eurocine Vaccines AB kr2.41 SEK +0.05
Genocea Biosciences Inc $10.99 USD +0.02
Vical Inc $0.91 USD +0.0156
View Industry Companies

Industry Analysis


Industry Average

Valuation GNVC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.7x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENVEC INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at